, Volume 12, Issue 5, pp 791-801
Date: 19 Aug 2005

Acetaldehyde-induced interleukin-1β and tumor necrosis factor-α production is inhibited by berberine through nuclear factor-κB signaling pathway in HepG2 cells

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

Alcoholic liver disease (ALD) is one of the most common liver diseases in the world. Increased levels of proinflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), have been correlated with the patients affected by ALD. However, the direct effect of alcohol in the induction of IL-1β and TNF-α has not been clarified. In this study, we demonstrated that acetaldehyde, the metabolic product of ethanol, was able to induce IL-1β and TNF-α production in HepG2 cells. Nuclear factor-κB (NF-κB), the transcription factor involved in the regulation of cytokine production, was also activated by acetaldehyde through inhibitory κB-α (IκB-α) phosphorylation and degradation. However, the NF-κB inhibitors, such as aspirin, cyclosporin A and dexamethasone, inhibited both the acetaldehyde-induced NF-κB activity and the induced cytokine production. Therefore, these data suggested that acetaldehyde stimulated IL-1β and TNF-α production via the regulation of NF-κB signaling pathway. By screening 297 controlled Chinese medicinal herbs supervised by Committee on Chinese Medicine and Pharmacy at Taiwan, we found that Coptis chinensis (Huang-Lien) and Phellodendron amurense (Huang-Po) were capable of inhibiting acetaldehyde-induced NF-κB activity. Berberine, the major ingredient of these herbs, abolished acetaldehyde-induced NF-κB activity and cytokine production in a dose-dependent manner. Moreover, its inhibitory ability was through the inhibition of induced IκB-α phosphorylation and degradation. In conclusion, we first linked the acetaldehyde-induced NF-κB activity to the induced proinflammatory cytokine production in HepG2 cells. Our findings also suggested the potential role of berberine in the treatment of ALD.